The effect of a cholecystokinin agonist on masseter muscle activity in the cat

Journal of Dental Research

Volumn 79, Issue 10, 2000, Pages 1823-1828

  Sitthisomwong, P ^a   Weiner, S ^b   Levin, L ^c   Reisman, S ^d   Siegel, A ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b RUTGERS SCHOOL OF DENTAL MEDICINE   (United States)

^c Department of Electrical Engineering   (United States)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Cholecystokinin agonist; Defensive rage; Electromyography; Masseter muscle

Indexed keywords

EID: 0034440738     PISSN: 00220345     EISSN: None     Source Type: Journal    
DOI: 10.1177/00220345000790101501     Document Type: Article

References (37)

1. Alexander GE, Crutcher MD, DeLong MR (1990). Basal gangliathalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontai" and "limbic" functions. Prog Brain Res 85:119-146.
2. Ashizawa T, Saito T, Takahata N (1996). Effects of ceruletide on perioral movements and the dopamine receptor-adenylate cyclase system in rats chronically treated with fluphenazine. Psychopharmacology 125:185-194.
3. Bickerdike MJ, Fletcher A, Marsden CA (1995). Attenuation of CCK-induced aversion in rats on the elevated x-maze by the selective 5-HTIA receptor antagonist WAY 100135 and WAY 100635. Neuropharmacology 34:805-811.
4. Block CH, Siegel A, Edinger H (1980). Effects of amygdaloid stimulation upon trigeminal sensory fields of the lip that are established during hypothalamically-elicited quiet biting attack in the cat. Brain Res 197:39-55.
5. Boyce S, Rupniak NM, Steventon M, Iversen SD (1990a). CCK-8S inhibits L-dopa-induced dyskinesias in Parkinsonian squirrel monkeys. Neurology 40:717-718.
6. Boyce S, Rupniak NM, Tye S, Steventon MJ, Iversen SD (1990b). Modulatory role for CCK-B antagonists in Parkinson's disease. Clin Neiiropharmacol 13:339-347.
7. Bradwejn J, Koszycki D, Payeur R, Bourin M, Borthwick H (1992). Replication of action of cholecystokinin tetrapeptide in panic disorders: clinical and behavioral findings. Am J Psychiatry 149:962-964.
8. Dafny N, Burks TF, Bergmann F (1983). Dose effects of morphine on the spontaneous unit activity recorded from the thalamus, hypothalamus, septum, hippocampus, reticular formation, central gray and caudate nucleus. JNeurosci Res 9:115-126.
9. Davis M (1992). The role of the amygdala in fear-potentiated startle: implications for animal models of anxiety. Trends Pharmacol Sci 13:35-41.
10. De Luca CJ (1984). Myoelectrical manifestations of localized muscular fatigue in humans. Cri t Rev Biomed Eng 11:251-279.
11. Della-Fera MA, Baile CA (1979). Cholecystokinin octapeptide: continuous picomole injections into the cerebral ventricles of sheep suppress feeding. Science 206:471-473.
12. Derrien M, McCort-Tranchepain I, Ducos B, Roques BP, Durieux C (1994). Heterogeneity of CCK-B receptors involved in animal models of anxiety. Pharmacol Biochem Behav 49:133-141.
13. Dworkin SF (1994). Perspectives on the interaction of biological, psychological and social factors in TMD. J Am Dent Assoc 125:856-863.
14. Flynn JP (1967). The neural basis of aggression in cats. In: Neurophysiology and emotion. Glass DC, editor. New York: Rockfeller University Press and Russell Sage Foundation. Flynn JP, Edwards SB, Bandler RJ Jr (1971). Changes in sensory and motor systems during centrally elicited attack. BehavSci 16:1-19.
15. Grzesiak RC (1991). Psychological considerations in temporomandibular dysfunction. Dent Clin North Am 35:209-225.
16. Harro J, Vasar E, Bradwejn J (1993). CCK in animal and human research on anxiety. Trends Pharmacol Sci 14:244-249.
17. Helton DR, Berger JE, Czachura JF, Rasmussen K, Kallman MJ (1996). Central nervous system characterization of the new cholecystokininB antagonist LY288513. Pharmacol Biochem Behav 53:493-502.
18. Hendrie CA, Neill JC, Shepherd JK, Dourish CT (1993). The effects of CCK A and CCK B antagonists on activity in the black/white exploration model of anxiety in mice. Physiol Behav 54:689-693.
19. Hess WR (1958). The functional organization of the diencephalon. New York: Grune and Stratton.
20. Hill RD, Woodruff ON (1990). Differentiation of central cholecystokinin receptor binding sites using the non-peptide antagonists MK-329 & L-365,260. Brain Res 526:276-283.
21. Hill RG, Boden P (1989). Electrophysiological actions of CCK in the mammalian CNS. In: The neuropeptide cholecystokinin (CCK): anatomy, biochemistry, receptors and physiology. Hughes, J, Dockray G, Woodruff GN, editors. Chichester: Ellis-Horwood, pp. 186-199.
22. Hokfelt T, Skirboll L, Rehfeld JF, Goldstein M, Markey K, Dann O (1980). A subpopulation of mesencephalic dopamine neurons projecting to limbic areas contains a cholecystokinin-like peptide: evidence from immunohistochemistry combined with retrograde tracing. Neuroscience 5:2093-2124.
23. Hutchinson RR, Renfrew JW (1978). Functional parallels between the neural and environmental antecedents of aggression. Neurosci Behav Rev 2:33-58.
24. Landgren S, Olsson KA (1980). The effect of electrical stimulation in the hypothalamus on the monosynaptic jaw closing and the disynaptic jaw opening reflexes in the cat. Exp Brain Res 39:389-400.
25. MacDonnell MF, Flynn JP (1966). Sensory control of hypothalamic attack. Anim Behav 14:399-405.
26. Maeda H, Maki S, Uchimura H (1988). Facilitatory effects of caerulein on hypothalamic defensive attack in cats. Brain Res 459:351-355.
27. Mogenson GJ, Jones DL, Yim CY (1980). From motivation to action: functional interface between the limbic system and the motor system. Prog Neurobiol 14:69-97.
28. Nishikawa T, Tanaka M, Koga I, Uchida Y (1985). Diphasic and long-lasting effect of ceruletide on tardive dyskinesia. Psychopharmacology 86:43-44.
29. Noble F, Derrien M, Roques BP (1993). Modulation of opioid antinociception by CCK at the supraspinal level: evidence of regulatory mechanisms between CCK and enkephalin systems in the control of pain. Br J Pharmacol 109:1064-1070.
30. Rudy TE, Turk DC, Kubinski JA, Zaki HS (1995). Differential treatment responses of TMD patients as a function of psychological characteristics. Pain 61:103-112.
31. Schwarting RK, Elstermeier F, Francke W, Huston JP (1995). Trigeminal-basal ganglia interaction: control of sensory-motor gating and positive reinforcement. Brain Res Bull 26:293-300.
32. Siegel A, Shaikh MB (1997). The neural basis of aggression and rage in the cat. Aggression and Violent Behavior 2:241-271.
33. Studier JM, Reibaud M, Tramu G, Blanc G, Glowinski J, Tassin JP (1984). Pharmacological study on the mixed CCK8/DA mesonucleus accumbens pathway: evidence for the existence of storage sites containing the two transmitters. Brain Res 298:91-97.
34. Vanderhaeghen JJ, Signeau JC, Gepts W (1975). New peptide in the vertebrate CNS reacting with anti-gastrin antibodies. Nature 257:601-605.
35. Van Kampen J, Frydryszak H, Stoessl AJ (1996). Behavioural evidence for cholecystokinin-dopamine D1 receptor interactions in the rat. Eur J Pharmacol 298:7-15.
36. 3H] dopamine from the nucleus accumbens of the rat. J Neurosci 5:2744-2749.
37. Weiner S, Shaikh MB, Siegel A (1993). Electromyographic activity in the masseter muscle resulting from stimulation of hypothalamic behavioral sites in the cat. J Orofac Pain 7:370-377.